News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Synthon Pharmaceuticals’s Anti-HER2 ADC Frontrunner SYD985 Outperforms Only Available HER2-targeting ADC


4/2/2014 9:31:05 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NIJMEGEN, Netherlands--(BUSINESS WIRE)--Synthon Biopharmaceuticals today announced the results of a head-to-head comparative program of its antibody-drug conjugate (ADC) SYD985 with Roche’s market leading anti-HER2 ADC, T-DM1 ( Kadcyla®*). SYD985 is a HER2-targeting ADC based on trastuzumab and Synthon’s proprietary cleavable linker-duocarmycin (vc-seco-DUBA) payload. Data support the potential of SYD985 to address the high unmet medical need of patients with HER2 2+ and HER2 1+ breast cancer for whom there is currently no effective therapy available.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES